Maravai LifeSciences Holdings, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Maravai LifeSciences Holdings, Inc. (MRVI) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $20.79 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-02-26
- Maravai LifeSciences Holdings, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $20.79, a 9.17% decline from fiscal 2024.
- Maravai LifeSciences Holdings, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $22.89, a 8.84% decline from fiscal 2023.
- Maravai LifeSciences Holdings, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $25.11, a 20.64% decline from fiscal 2022.
- Maravai LifeSciences Holdings, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $31.64, a 9.86% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $20.79 10-K · filed 2026-02-26 |
| 2024-12-31 | $22.89 10-K · filed 2025-03-18 |
| 2023-12-31 | $25.11 10-K · filed 2024-02-29 |
| 2022-12-31 | $31.64 10-K · filed 2023-02-28 |
| 2021-12-31 | $28.80 10-K · filed 2022-03-01 |